about
Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromesClopidogrel: a review of its use in the prevention of thrombosisRomiplostim.Miglustat: a review of its use in Niemann-Pick disease type C.Nelarabine.Spotlight on lenalidomide in relapsed or refractory multiple myeloma.Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.Docetaxel: a review of its use in metastatic breast cancer.Tamsulosin: an update of its role in the management of lower urinary tract symptoms.Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.Adalimumab: in Crohn's disease.Degarelix.Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure.Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Extended-release methylphenidate (Ritalin LA).Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.Pranlukast: a review of its use in the management of asthma.Linezolid: in infants and children with severe Gram-positive infections.Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease.Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.Aripiprazole: in acute mania associated with bipolar I disorder.Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.Tolcapone: a review of its use in the management of Parkinson's disease.Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.Moxonidine: a review of its use in essential hypertension.Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer.Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes.Insulin lispro: a review of its use in the management of diabetes mellitus.Sitagliptin.Etanercept: a review of its use in the management of rheumatoid arthritis.Topiramate: a review of its use in the treatment of epilepsy.Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma.
P50
Q28219579-BFFCCDA4-8360-42A0-83F7-5500D7B76D5DQ28220732-5B7EB8A3-9E85-4920-820B-40152724E249Q33383635-B6510372-D3A3-4436-AA32-898CA9F0A4CBQ33460275-2E2A7FAB-DF02-4E9E-A511-64E17499751FQ34010279-506847CE-3040-43A5-9D2B-BD2F889DD33AQ34028642-7465EE8F-5337-41AE-818D-0CFD6595B96DQ34028864-43A27C45-C3F8-4073-A621-1B4214B2664BQ34165509-7A8A6224-A859-47F1-9E76-1CD7C0FA0F48Q34304485-EFC227D9-3DFA-49E0-BD11-2362DC29466DQ34457098-25BC7E8A-1600-4059-80F1-A8454E8D0B5EQ34468674-A3CF18A7-1E57-47BA-8291-BFF0819A7F26Q34492626-66FFF766-5850-4116-952D-42E34DA114ECQ34554493-C31C6F70-1907-45D3-B4A1-4AF73B9CB212Q34578295-EAF049AE-5A73-4CBE-AB71-44D527A14B52Q34611725-B4DB751A-9799-487B-8DB7-63304C906BB5Q34634131-4A86FCA0-CDDE-4950-A713-A9E91627AF3DQ34960317-0471848A-66E0-4B45-B7BD-A927EAB7E574Q34967113-C131C637-6546-426B-AF02-704B3C06CE52Q34967215-51E7011C-9D37-4024-8A97-6CEDCA0BCDB1Q35109122-41D951A1-3C3C-4DE7-84C4-CE883E85A050Q35135386-3FA64A7B-89B8-47D5-9FC4-56FA7D6D856DQ35213448-383EB2EF-6467-4E4C-8AC2-4AE394A02D97Q35627818-FC885075-01F0-41EE-951C-8A50FCE35E79Q35632732-680048FF-F502-4219-8040-BBFE2882AD60Q35747870-EA371FE4-4CD8-49DD-A722-A54D98FB6ABFQ35938511-E78444C1-3DE7-4283-87C7-297B711CE593Q36033310-6D4E41D2-8235-474A-A58D-395DDFC5856DQ36062016-F7518535-9CB4-4BF2-B2B8-75870F1438A0Q36139277-E65762B7-C3D8-468F-8CF2-6DF8EEA1839CQ36214689-C042903D-BACD-4596-BC51-9A6AA0B45201Q36441455-CBBAE3C0-9E94-4C74-9D93-D008F8A0A5F9Q36489184-9FF1DD34-BF78-4F2E-B98A-E8CD0D5FFD58Q36509251-6CF2D9E2-57F8-40E2-96DA-E758DCCB7310Q36650095-0F4E52C6-55EA-4DBD-8157-60D4739A2D84Q36688916-E9066EDA-0FEB-478C-B657-F5EE54F14A88Q36750094-A530AA04-7ED7-4642-926F-5DCD689C765EQ36757596-1ADD7AF4-589F-4454-A65D-922CA88B7AE0Q36830130-6E0A2916-8BB1-4718-ADF7-B5B9C85DF5EBQ36967168-87458426-1512-4F30-B745-FAEE9604FF09Q36993396-A994324B-C95E-411A-9342-0F4320BEE02B
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Katherine A Lyseng-Williamson
@ast
Katherine A Lyseng-Williamson
@en
Katherine A Lyseng-Williamson
@es
Katherine A Lyseng-Williamson
@nl
Katherine A Lyseng-Williamson
@sl
type
label
Katherine A Lyseng-Williamson
@ast
Katherine A Lyseng-Williamson
@en
Katherine A Lyseng-Williamson
@es
Katherine A Lyseng-Williamson
@nl
Katherine A Lyseng-Williamson
@sl
altLabel
Katherine Lyseng-Williamson
@en
Katherine Williamson
@en
prefLabel
Katherine A Lyseng-Williamson
@ast
Katherine A Lyseng-Williamson
@en
Katherine A Lyseng-Williamson
@es
Katherine A Lyseng-Williamson
@nl
Katherine A Lyseng-Williamson
@sl
P214
P950
P106
P1153
8072189500
P21
P214
P31
P496
0000-0002-5104-1158
P735
P7859
viaf-315088620